Impact of denosumab compared with zoledronic acid on renal function in the treatment of myeloma bone disease

Noopur S. Raje, MD
Massachusetts General Hospital Cancer Center
Boston, MA

Background: Osteolytic bone disease and renal dysfunction are complications of multiple myeloma. ZA, used for the prevention and treatment of bone complications, can be nephrotoxic. DMB inhibits RANKL and thereby osteoclast function, and is not renally cleared. This international, phase III, randomized, double blind study evaluates the efficacy and safety of DMB compared with ZA in newly diagnosed myeloma patients (pts).

Author(s): Noopur S. Raje, G. David Roodman, Wolfgang Willenbacher, Kazuyuki Shimizu, Ramon Garcia-Sanz, Brian G. Durie, Li Zhu, Paul C. Cheng, Sumita Bhatta, Evangelos Terpos; Massachusetts General Hospital Cancer Center, Boston, MA; Indiana University, Indianapolis, IN; Medical University of Innsbruck, Innsbruck, Austria; National Hospital Organization Higashi Nagoya National Hospital, Nagoya, Japan; Hospital Universitario de Salamanca, Salamanca, Spain; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; Amgen Inc., Thousand Oaks, CA; National and Kapodistrian University of Athens, Athens, Greece

Clinical trial information: NCT01345019